1. Home
  2. BTBD vs GOVX Comparison

BTBD vs GOVX Comparison

Compare BTBD & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BT Brands Inc.

BTBD

BT Brands Inc.

N/A

Current Price

$1.85

Market Cap

7.1M

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$0.48

Market Cap

3.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTBD
GOVX
Founded
1987
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
3.8M
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
BTBD
GOVX
Price
$1.85
$0.48
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
37.6K
668.0K
Earning Date
05-15-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,823,472.00
$2,489,145.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.12
52 Week High
$2.48
$4.40

Technical Indicators

Market Signals
Indicator
BTBD
GOVX
Relative Strength Index (RSI) 78.53 30.72
Support Level $1.25 $0.14
Resistance Level $1.99 $0.86
Average True Range (ATR) 0.10 0.07
MACD 0.04 -0.01
Stochastic Oscillator 88.66 6.76

Price Performance

Historical Comparison
BTBD
GOVX

About BTBD BT Brands Inc.

BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: